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PURPOSE: The prognostic value of SMAD4 in pancreatic cancer has been evaluated in several studies. However,
the conclusions remain controversial. Therefore, we aimed to evaluate the association between SMAD4
expression and the outcome of pancreatic cancer patients by performing a meta-analysis. METHODS: We
systematically searched for relevant studies evaluating the relationship between SMAD4 expression and the
outcome of pancreatic cancer patients until May 2015. A meta-analysis was performed using STATA 12.0, and
pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were used to estimate the strength of the
association between SMAD4 expression and the prognosis of pancreatic cancer patients. RESULTS: The analysis
included 1762 patients from 14 studies, with 1401 patients from 11 studies and 927 patients from 8 studies
included in the univariate and multivariate analyses, respectively. Loss of SMAD4 expression was found to be
significantly correlated with poor overall survival, with the combined HR (95% CI) of 1.20 (1.03-1.40). After
adjusting for potential confounders using the Cox regression model, the pooled HR (95% CI) was 1.88 (1.31-2.70).
In subgroup analysis, study region, number of patients, follow-up duration, and cutoff value were found to affect
the significance of the association between loss of SMAD4 expression and poor prognosis. In addition, there was
no evidence of publication bias, as suggested by Begg’s and Egger’s test. CONCLUSIONS: Loss of SMAD4 was
associated with poor survival and was a negative prognostic indicator in patients with pancreatic cancer.
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Pancreatic cancer is the eighth leading cause of cancer-related deaths
worldwide [1]. Surgery remains the primary treatment modality and
the only chance of cure. However, more than 80% of patients have
advanced disease at presentation (metastasis or invasion of the
superior mesenteric artery or celiac trunk in case of locally advanced
tumors), which makes the tumor unsuitable for surgical resection [2].
Even if resection can be performed, the median survival is still only 18
months [3]. Despite the improvements in diagnostic and therapeutic
techniques for pancreatic cancer over the past few decades, the
prognosis is still poor, with an estimated survival of only 5.8% at 5
years [4,5]. Clinicopathological characteristics, for example, tumor
size and stage, cannot reliably predict individual clinical outcomes.
Thus, the identification of accurate molecular prognostic factors may
contribute to a better understanding of cancer development and
clinical outcome and eventually facilitate the rational selection of
therapeutic strategies.Pancreatic cancer is a genetic disease characterized by somatic
mutations. An important genetic change in pancreatic cancer is the
SMAD4 mutation, which leads to the loss of SMAD4 protein
expression. SMAD4 is a tumor suppressor gene that is inactivated in
Figure 1. Flow diagram of the selection procedure of studies.
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mutation of one allele in combination with the loss of the other allele
or by homozygous deletion of both alleles [7]. In the cytoplasm,
SMAD4 mediates signals from a family of transforming growth
factor-β ligands and their transmembrane receptors through the
phosphorylation of SMAD proteins, which heterodimerize with
SMAD4. This SMAD4/SMAD complex transmits upstream signals
by translocating to the nucleus, binding to specific DNA sequences,
and activating gene transcription.
Recently, many studies demonstrated that the loss of SMAD4
protein expression was associated with lymph node metastasis and
TNM stage in pancreatic cancer patients [8,9]. Moreover, its
prognostic role in pancreatic cancer has been widely investigated
[10–12].
However, the results are conflicting. Many studies have shown that
the loss of SMAD4 expression is positively associated with poor
prognosis [12,13]. However, other studies have found no correlation
between the loss of SMAD4 expression and a poor clinical outcome
[7,8]. Whether the discrepancies in these data are due to limited sample
sizes or genuine heterogeneity is still unknown. Thus, current clinical
data are insufficient to determine the prognostic value of SMAD4 in
pancreatic cancer. Accordingly, to clarify the exact prognostic value of
SMAD4 in pancreatic cancer, we conducted a meta-analysis of eligible
studies to investigate the association between the loss of SMAD4
expression and the prognosis of pancreatic cancer patients.
Materials and Methods
Search Strategy
This meta-analysis was performed in accordance with the Preferred
Reporting Items for Systematics Reviews and Meta-Analyses
guidelines [14]. A comprehensive literature search of the electronic
databases PubMed, Embase, and Web of Science was performed up
to May 20, 2015. Studies were selected using the following search
terms: SMAD4 or DPC4 and cancer or tumor or carcinoma or neoplasm
and prognosis or prognostic or outcome and pancreatic. The references of
articles and reviews identified through the search were also manually
searched for the possible inclusion of additional studies.
Study Selection
To be eligible for inclusion in this meta-analysis and data
extraction, studies had to 1) be on patients with pancreatic cancer,
2) provide overall survival (OS) data to evaluate the role of SMAD4
expression in the prognosis of pancreatic cancer patients, 3) provide
hazard ratios (HRs) with 95% confidence intervals (CIs) or enable
calculation of these statistics from the data presented, 4) classify
SMAD4 expression as “high” and “low” or “positive” and “negative”,
and 5) be published as a full paper in English. The exclusion criteria
were 1) data from review, animal, or cell line studies; 2) no
information on survival; and 3) publication in any language other
than English. In cases of multiple publications on the same
population, only the most recent or the most complete study was
included in the analysis.
Data Extraction and Quality Assessment
Two investigators reviewed each eligible article independently and
extracted information from all publications meeting the inclusion
criteria. The following information was culled from each study: first
author name, publication year, country where the research was
performed, number of patients, mean or median age of patients,histology, disease stage, follow-up duration, detection method,
antibody used and its dilution, cutoff value for positivity, and OS
data. OS was defined as the interval between initial diagnosis and
death. Inconsistencies in the research process were resolved through
debate and consultations.
The quality of each eligible study was assessed using the
Newcastle-Ottawa quality assessment scale [15]. The scale includes
eight items on methodology under three main dimensions:
selection (four items, one point for each item), comparability
(one item, up to two points), and outcome (three items, one point
for each item). Item scores were added up and used to
quantitatively compare study quality. A higher score indicated
higher quality. Inconsistencies in the scoring were resolved
through discussion and consultations.
Statistical Methods
The HR and 95% CI were used to estimate the effect of the loss of
SMAD4 expression on the prognosis of patients with pancreatic
cancer. For multivariate analysis, the HRs (95% CIs) were computed
using the Cox regression model. If the HRs (95% CIs) were not
provided directly in the articles, we contacted the authors to gain
more information or calculated these using the methods provided by
Tierney et al. [16].We used the Cochran’sQ test (P b .10, significant
heterogeneity) and the I2 statistic (I2 ≤ 50%, no or moderate
heterogeneity; I2 N 50%, strong heterogeneity) to estimate the
heterogeneity among studies. The random-effects model was used to
pool the HRs (95% CI) in case of significant heterogeneity (P b .10
or I2 N 50%); otherwise, the fixed-effects model was used. A
sensitivity analysis was performed by removing one study at a time to
estimate the stability of the results. Publication bias was assessed
using the funnel plot and Egger’s test. All the analyses were
performed using STATA 12.0 software (Stata Corporation, College
Station, TX).
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Study Characteristics
We searched articles from PubMed, Web of Science, and Embase
systematically, and 564 potentially relevant articles were identified.
After reading the titles, abstracts, tables, figures, and key data
carefully, 14 articles [7–13,17–23] with 1762 patients were found to
meet the eligibility criteria and were included in the meta-analysis
(Figure 1). The characteristics of these studies are listed in Table 1.
SMAD4 expression in all studies was evaluated using immunohis-
tochemistry. The cutoff value for negative versus positive SMAD4
staining varied among the studies. Positivity was determined by
visible staining in nine studies, whereas different scores were used as
the cutoff value in the other studies. The included studies were of
high quality.
Loss of SMAD4 Expression and Prognosis in Pancreatic Cancer
Among the 14 studies eligible for estimating the correlation
between the loss of SMAD4 expression and OS, 11 were suitable for
univariate analysis and 8 for multivariate analysis (Figure 2); the rest
could not be included because of insufficient data. For univariate
analysis, because of the significant heterogeneity between studies (I2 =
58.8%, P = .007), the random-effects model was used to combine the
effect of the loss of SMAD4 expression and the pooled HR (95% CI)
was 1.20 (1.03-1.40), indicating that the loss of SMAD4 expression
predicted poor OS in pancreatic cancer patients. Considering the
potential confounding factors and significant heterogeneity between
studies (I2 = 71.0%, P = .001), the pooled HR (95% CI) of the loss of
SMAD4 expression for OS was 1.88 (1.31-2.70) after adjusting for
age, tumor size, differentiation, stage, lymph node status, and grade.Table 1. Characteristics of the Eligible Studies
First Author Year Country Number of Patients
(Enrolled/Positive/
Negative)
Age
(Years)
Histology Stage
(I-II/III-IV)
Follo
(Med
Mon
Javel M 2014 USA 81/47/34 Mean
60.6
PDAC 8/83 NA
Bachet JB 2012 France 453/166/287 Median
63.0
PAC 453/0 54
Biankin AV 2002 Australia 119/56/63 Mean
64.0
PDAC 29/100 3.5
Oshima M 2013 Japan 106/42/64 Mean
68.0
PDAC 106/0 17.3
Kadera BE 2013 USA 32/16/16 Median
60.0
PDAC 0/32 48.9
Ottenhof NA 2012 Netherlands 78/44/34 Mean
63.0
PDAC 20/58 NA
Voorneve ld
PW
2013 Netherlands 41/19/22 NA PDAC NA NA
Jiang H 2012 China 70 Mean
59.0
PDAC 160/2 NA
Yamada S 2015 Japan 174/70/104 Mean
63.7
PDAC 150/24 16.7
Toga T 2004 Japan 88/13/75 Mean
65.9
IDC 17/71 NA
Tascilar M 2001 USA 249/111/138 Mean
65.4
PAC 59/190 17
Kborana AA 2005 USA 124/59/65 Mean
66.5
PDAC 67/57 16
Yamazaki K 2014 Japan 113/46/67 NA PDAC NA NA
Hua Z 2003 China 34/26/8 Mean
55.2
PAC 18/16 NA
IHC: immunohistochemistry, HR (95% CI): hazard ratio (95% confidence interval), NA: not available
adenocarcinoma.We performed a subgroup analysis of the correlation between the
loss of SMAD4 and OS by study region, patient age, sample size,
follow-up duration, tumor stage, and cutoff value. The results are
listed in Tables 2 and 3.
In univariate analysis, the loss of SMAD4 expression was
significantly associated with poor OS in the studies with Asian
patients (HR: 1.19, 95% CI: 1.03-1.38), those with sample sizes of
≤100 (HR: 1.36, 95%CI: 1.18-1.56), and those with a cutoff value of
0 (HR: 1.21, 95% CI: 1.08-1.34). In all other subgroups, loss of
SMAD4was not significantly associated with poor OS. Inmultivariate
analysis, the pooled HRs indicated that SMAD4 expression was not
significantly associated with poor OS only in the subgroup with a
cutoff value N0 (HR: 1.24, 95% CI: 0.84-1.84). In the multivariate
analysis, we noted that studies in whichmore than 80%of patients had
stage I to II disease may have had a poorer OS (HR: 2.91, 95% CI:
1.51-5.61) than did those with fewer stage I to II patients (HR: 1.53,
95% CI: 1.11-2.10). This result suggests that the loss of SMAD4
might be more relevant in patients with less advanced disease.
Publication Bias Assessment
We used Begg’s funnel plot and Egger’s test to evaluate publication
bias (Figure 3). For both univariate and multivariate analyses, no
funnel plot asymmetry was found. Moreover, Egger’s test did not
indicate significant funnel plot asymmetry (P = .441 for univariate
analysis; P = .173 for multivariate analysis). Therefore, publication
bias was not detected in the meta-analysis.
Sensitivity Analysis
We used the leave-one-out method for sensitivity analysis by
removing one study at a time to determine whether any single studyw-up
ian/
ths)
Method Antibody
(Dilution)
Cutoff
(%)
Univariate Analysis
HR (95% CI)
Multivariate
Analysis HR
(95% CI)
Study
Quality
Score
IHC Proteintech Group
1:450
N0 NA 1.190
(0.730-1.961)
6
IHC Santa 1:50 N0 1.087
(0.855-1.389)
NA 9
IHC Santa N5 0.60 (0.41-0.89) 1.14
(0.71-1.81)
7
IHC Santa 1:100 N0 NA 2.045
(1.154-3.624)
8
IHC Santa 1:100 N0 4.9 (1.4-16.6) 9.3 (2.0-42.5) 7
IHC Santa 1:300 N0 1.354
(1.082-1.693)
2.34
(1.30-4.21)
8
IHC Santa 1:1600 Score N
1
1.379
(1.015-1.876)
NA 6
IHC Abcam 1:15 Score N
3
1.94 (0.98-3.84) NA 7
IHC Santa 1:100 N0 NA 4.004
(2.488-6.666)
7
IHC Santa 1:100 N10 1.362
(1.015-1.832)
1.536
(0.744-3.175)
6
IHC Santa 1:100 N0 1.36 (1.03-1.81) 1.36
(1.01-1.83)
9
IHC Santa 1:400 N5 1.136
(0.769-1.695)
NA 9
IHC Santa N0 1.125
(0.932-1.357)
NA 7
IHC Santa 1:100 N0 1.031
(0.694-1.533)
NA 6
, PDAC: pancreatic ductal adenocarcinoma, PAC: pancreatic adenocarcinoma, IDC: invasive ductal
Figure 2. Forest plot showing the association between the loss of SMAD4 expression and OS in pancreatic cancer using univariate and
multivariate analyses. (A) Univariate analysis. (B) Multivariate analysis.
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that the studies by Ottenhof et al. [13] and Tascilar et al. [11]
significantly influenced the pooled HR in univariate analysis.
However, the result was stable and not obviously influenced by any
single study in multivariate analysis.
Discussion
Pancreatic cancer is associated with the highest mortality rates among
malignant conditions worldwide. Its prognosis is poor, although
various treatment options have been applied. Currently, surgical
resection is still the only curative treatment for pancreatic cancer and
the only method to improve survival. In addition, adjuvant systemic
treatment also plays a role in the treatment of pancreatic cancer.
Despite recent improvements in survival, most patients who undergo
surgical resection and adjuvant treatment ultimately die of the disease.
This necessitates the identification of more sensitive and specific
prognostic indicators to accurately predict a response to treatment.
SMAD4, which is a mediator between extracellular growth factorsfrom the transforming growth factor-β family and genes inside the cell
nucleus, has been reported to be related with the prognosis of cervical
cancer [24,25], colorectal cancer [26], hepatocellular carcinoma [27],
and gastric cancer [28]. Studies have shown that the loss of SMAD4
expression is closely associated with tumor prognosis in pancreatic
cancer as well.
In recent years, SMAD4 expression has been shown to be
associated with disease progression in pancreatic ductal adenocarci-
noma [29,30], where the loss of SMAD4 expression was associated
with distant metastasis. However, reports on the association of
SMAD4 expression with patient survival are inconsistent. For
example, Bachet et al. [17] reported that the loss of SMAD4
expression was not significantly associated with survival in pancreatic
cancer patients and could not be viewed as a prognostic marker.
Furthermore, Biankin et al. [19] even found that the loss of SMAD4
was associated with improved outcomes in pancreatic cancer patients
(HR: 0.60, 95% CI: 0.41-0.89). Therefore, to verify the true
relationship between the loss of SMAD4 expression and the prognosis
Table 2. Stratified Analysis of Pooled HRs for Pancreatic Cancer Patients Using Univariate Analysis
Variable No. of
Studies
No. of
Patients
HR(95% CI) Heterogeneity Model
Used
χ2 I2 P Value
Region
Asian 4 305 1.19 (1.03-1.38) 3.62 17.1% .306 Fixed
Non-Asian 7 1096 1.19 (0.94-1.50) 20.63 70.9% .002 Random
Age (mean)
N60 5 658 1.14 (0.88-1.49) 14.93 73.2% .005 Random
≤60 2 104 1.33 (0.72-2.43) 2.46 59.4% .117 Random
Stage
N80% 2 523 1.33 (0.77-2.27) 2.45 59.3% .117 Random
≤80% 7 724 1.18 (0.92-1.52) 20.47 70.7% .002 Random
Follow-up
N36 2 485 2.03 (0.47-8.70) 5.49 81.8% .019 Random
≤36 3 492 0.99 (0.61-1.60) 11.40 82.5% .003 Random
No. of patients
N100 5 1058 1.05 (0.85-1.31) 11.64 65.6% .02 Random
≤100 6 343 1.36 (1.18-1.56) 7.05 29.1% .217 Fixed
Cutoff
0 6 959 1.21 (1.08-1.34) 8.50 41.1% .131 Fixed
N0 5 442 1.17 (0.83-1.64) 15.65 74.4% .004 Random
igure 3. Begg’s funnel plot for all studies included in this
eta-analysis. (A) Univariate analysis. (B) Multivariate analysis.
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including recent related studies, using a comprehensive search
strategy. We found that the loss of SMAD4 expression was a
significant predictor for OS in patients with pancreatic cancer. The
pooled HRs (95% CIs) were 1.20 (1.03-1.40) for univariate analysis
and 1.88 (1.31-2.70) for multivariate analysis. In addition, for the
multivariate analysis, the sensitivity analysis indicated that the
significant association between the loss of SMAD4 expression and
poor OS was not altered, regardless of whether one of these studies
was omitted, suggesting the robustness of this result. However, for the
univariate analysis, the result was significantly influenced by two
studies, Ottenhof et al. and Tascialar et al., and after being excluded,
the pooled HRs (95% CIs) were 1.1827 (0.9952-1.4055) and 1.1843
(0.9998-1.4029), respectively. To some degree, potential confound-
ing factors might increase the heterogeneity among studies and
influence the results of univariate analysis. All studies included in this
meta-analysis were found to be of high quality.
For both univariate and multivariate analyses, the heterogeneity
among studies was found to be strong. To decrease this heterogeneity,Table 3. Stratified Analysis of Pooled HRs for Pancreatic Cancer Patients Using Multivariate
Analysis
Variable No. of
Studies
No. of
Patients
HR (95% CI) Heterogeneity Model
Used
χ2 I2 P Value
Region
Asian 3 368 2.43 (1.37-4.30) 5.65 64.6% .059 Random
Non-Asian 5 559 1.55 (1.07-2.26) 10.00 60.0% .04 Random
Age (mean)
N60 7 895 1.75 (1.24-2.46) 20.07 70.1% .003 Random
≤60 NA
Stage
N80% 2 280 2.91 (1.51-5.61) 3.04 67.1% .081 Random
≤80% 6 647 1.53 (1.11-2.10) 10.04 50.2% .074 Random
Follow-up
N36 1 32 9.3 (2.0-42.5)
≤36 4 648 1.86 (1.09-3.15) 16.97 82.3% .001 Random
No. of patients
N100 4 648 1.86 (1.09-3.15) 16.97 82.3% .001 Random
≤100 4 279 1.95 (1.09-3.51) 7.96 62.3% .047 Random
Cutoff
0 6 720 2.17 (1.37-3.42) 21.61 76.9% .001 Random
N0 2 207 1.24 (0.84-1.84) 0.46 0% .498 FixedF
mmuch attention should be paid to the baseline characteristics of
patients, which might have affected the conclusion of each study that
was included in the meta-analysis. These baseline characteristics
included patient age, study region, sample size, follow-up duration,
tumor clinical stage, and cutoff value for the definition of positive
staining. Therefore, further subgroup analysis was performed
according to these baseline characteristics. The results of subgroup
analysis should be interpreted because of the existence of heteroge-
neity among studies and the small sample size. In the subgroups
where no significant association was found between the SMAD4
expression and the prognosis, strong heterogeneity existed among
these studies, and random-effect model was chosen to pool the HRs.
Therefore, we also performed multivariate analysis. In the multivar-
iate analysis, the HR was adjusted by potential confounding factors,
and the pooled HRs indicated that only in the subgroup where the
cutoff value was more than 0 was the loss of SMAD4 expression not
significantly associated with the poor OS (HR: 1.24, 95% CI:
0.84-1.84). This may because of the lack of a uniform standard for
defining positive SMAD4 expression. The cutoff value greatly varied
among studies, and this may have affected the study results.
Several limitations of this meta-analysis must be acknowledged, as
we could not completely eliminate potential bias. First, the studies
included in our meta-analysis were restricted to those published in
English, and the number of studies is small. Therefore, we could not
analyze the association between SMAD4 expression and disease-free
survival as only one study [12] reported this association (HR: 1.888,
Figure 4. Effect of individual studies on the pooled HR for OS. (A)
Univariate analysis. (B) Multivariate analysis.
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heterogeneity. Different patient selection criteria, treatment proto-
cols, and detection methods for SMAD4 expression are possible
explanations for the heterogeneity. For example, the expression of
SMAD4 was determined by immunohistochemistry in all the
included studies. However, differences in the primary antibody
type and concentration could affect the results of immunohisto-
chemistry, resulting in heterogeneity among studies. Therefore, a
random-effects model was adopted, and subgroup analysis was
performed to minimize the effect of this limitation. Third, although
we extracted HRs and 95% CIs using the strategies reported by
Tierney et al. [16], the data calculated from the Kaplan-Meier curve
or log-rank test may not be as precise as obtaining data directly from
the original article. In addition, although Begg’s funnel plot and
Egger’s test indicated no publication bias, this could still influence the
results and lead to a false-positive association. An asymmetrical funnel
plot may indicate publication bias or be due to an inflated estimate in
small studies of low quality. Thus, although the funnel plot is often
used to assess publication bias, it should be noted that the asymmetry
may also be due to other sources of bias [31].
Conclusions
In conclusion, pancreatic cancer patients with loss of SMAD4
expression were found to have shorter OS in multivariate analysis as
well as subgroup analysis. Therefore, it can be considered a poorpredictor of survival in patients with pancreatic cancer. SMAD4
expression assessment could provide more detailed information for
patients with pancreatic cancer and could be used to optimize
therapeutic schemes. Further studies, especially large well-matched
prospective studies, are needed to clarify the prognostic value of
SMAD4 for survival in patients with pancreatic cancer.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2015.11.007.
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